The TNF-α transgenic mouse model of inflammatory arthritis

[1]  Richard W. Martin,et al.  Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. , 2002, Arthritis and rheumatism.

[2]  W. Min,et al.  Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[3]  G. Kollias,et al.  Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. , 2002, Arthritis and rheumatism.

[4]  S. Mita,et al.  Differential effects between marimastat, a TNF-α converting enzyme inhibitor, and anti-TNF-α antibody on murine models for sepsis and arthritis , 2002 .

[5]  T. Martin,et al.  Involvement of receptor activator of NFκB ligand and tumor necrosis factor-α in bone destruction in rheumatoid arthritis , 2002 .

[6]  F. Kainberger,et al.  Adenovirus-based overexpression of tissue inhibitor of metalloproteinases 1 reduces tissue damage in the joints of tumor necrosis factor alpha transgenic mice. , 2001, Arthritis and rheumatism.

[7]  A R Pettit,et al.  TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.

[8]  M. Karin,et al.  Signal transduction by tumor necrosis factor and its relatives. , 2001, Trends in cell biology.

[9]  E. Schwarz,et al.  Degradative Pathways in Tissues of the Temporomandibular Joint , 2001, Cells Tissues Organs.

[10]  I. Wicks,et al.  Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. , 2001, The Journal of clinical investigation.

[11]  G. Panayi,et al.  Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.

[12]  R. Locksley,et al.  The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.

[13]  E. Schwarz,et al.  Efficacy of Etanercept for Wear Debris‐Induced Osteolysis , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[14]  Y. Sasaguri,et al.  Suppression of adjuvant arthritis of rats by a novel matrix metalloproteinase‐inhibitor , 2000, British journal of pharmacology.

[15]  R N Maini,et al.  Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.

[16]  S. Goldring.  The final pathogenetic steps in focal bone erosions in rheumatoid arthritis , 2000, Annals of the rheumatic diseases.

[17]  M. Feldmann,et al.  Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor α , 2000, Annals of the rheumatic diseases.

[18]  G. Kollias,et al.  Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. , 2000, The Journal of biological chemistry.

[19]  Y. Okada,et al.  Expression and Tissue Localization of Membrane-Types 1, 2, and 3 Matrix Metalloproteinases in Rheumatoid Synovium , 2000, Laboratory Investigation.

[20]  T. Martin,et al.  Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. , 2000, Arthritis and rheumatism.

[21]  W. Hunter,et al.  Taxol (paclitaxel) involution of articular cartilage destruction in collagen induced arthritis: an ultrastructural demonstration of an increased superficial chondroprotective layer. , 2000, The Journal of rheumatology.

[22]  T. Martin,et al.  Activated T lymphocytes support osteoclast formation in vitro. , 1999, Biochemical and biophysical research communications.

[23]  L. Hofbauer,et al.  Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. , 1999, European journal of endocrinology.

[24]  D. Lacey,et al.  Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells , 1999 .

[25]  George Kollias,et al.  On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease , 1999, Immunological reviews.

[26]  W. Bode,et al.  Insights into MMP‐TIMP Interactions , 1999, Annals of the New York Academy of Sciences.

[27]  L. Matrisian,et al.  Measurement of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Blood and Tissues: Clinical and Experimental Applications , 1999, Annals of the New York Academy of Sciences.

[28]  G. Kollias,et al.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. , 1999, Immunity.

[29]  D. Walsh,et al.  Angiogenesis and arthritis. , 1999, Rheumatology.

[30]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[31]  P. Blackshear,et al.  Feedback Inhibition of Macrophage Tumor Necrosis Factor-α Production by Tristetraprolin , 1998 .

[32]  T. Hotokebuchi,et al.  Induction of abundant osteoclast-like multinucleated giant cells in adjuvant arthritic rats with accompanying disordered high bone turnover. , 1998, Histology and histopathology.

[33]  Y. Suzuki,et al.  Osteoclast-like cells in murine collagen induced arthritis. , 1998, The Journal of rheumatology.

[34]  A. Koch,et al.  Angiogenesis: Implications for rheumatoid arthritis , 1998 .

[35]  R. Effros,et al.  Transgenic mice expressing a truncated Peromyscus leucopus TNF-alpha gene manifest an arthritis resembling ankylosing spondylitis. , 1998, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[36]  T. Thornhill,et al.  Identification of cell types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid arthritis. , 1998, The American journal of pathology.

[37]  G. Kollias,et al.  Interleukin 6 Is Required for the Development of Collagen-induced Arthritis , 1998, The Journal of experimental medicine.

[38]  G. Kollias,et al.  A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling , 1997, European journal of immunology.

[39]  G. Kollias,et al.  DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition. , 1997, Journal of immunology.

[40]  R. Huber,et al.  Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1 , 1997, Nature.

[41]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[42]  M. Feldmann,et al.  Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. , 1997, British journal of rheumatology.

[43]  G. Ciliberto,et al.  Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. , 1997, Immunity.

[44]  Nicole Nelson,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.

[45]  W. Lesslauer,et al.  Attenuation of collagen-induced arthritis in 55-kDa TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. , 1996, Journal of immunology.

[46]  B. Haynes,et al.  A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. , 1996, Immunity.

[47]  R. Clark,et al.  Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor , 1995, The Journal of experimental medicine.

[48]  G. Kollias,et al.  The type I interleukin‐1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF‐transgenic mice , 1995, European journal of immunology.

[49]  T. Kishimoto,et al.  Interleukin-6 (IL-6) induces the proliferation of synovial fibroblastic cells in the presence of soluble IL-6 receptor. , 1995, British journal of rheumatology.

[50]  M. Feldmann,et al.  Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease , 1995, Immunological reviews.

[51]  R. Strieter,et al.  Cytokines in Rheumatoid Arthritis , 1998, Drugs & aging.

[52]  E. Brahn,et al.  A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. , 1995, Cellular immunology.

[53]  W. Fiers,et al.  Molecular mechanisms of tumor necrosis factor‐induced cytotoxicity , 1994, FEBS letters.

[54]  N. Udagawa,et al.  Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Y. Nagai,et al.  The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells , 1993, Clinical and experimental immunology.

[56]  E. Brahn,et al.  Angiogenesis inhibition suppresses collagen arthritis , 1992, The Journal of experimental medicine.

[57]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[58]  E. Chen,et al.  Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[59]  L. Gooding,et al.  A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact , 1990, Cell.

[60]  M. Lark,et al.  Discoordinate expression of stromelysin, collagenase, and tissue inhibitor of metalloproteinases-1 in rheumatoid human synovial fibroblasts. Synergistic effects of interleukin-1 and tumor necrosis factor-alpha on stromelysin expression. , 1990, The Journal of biological chemistry.

[61]  R. Maki,et al.  Quantitative analysis of cytokine gene expression in rheumatoid arthritis. , 1990, Journal of immunology.

[62]  C V Jongeneel,et al.  Kappa B-type enhancers are involved in lipopolysaccharide-mediated transcriptional activation of the tumor necrosis factor alpha gene in primary macrophages , 1990, The Journal of experimental medicine.

[63]  M. Feldmann,et al.  INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.

[64]  B. Gitter,et al.  Characteristics of human synovial fibroblast activation by IL-1 beta and TNF alpha. , 1989, Immunology.

[65]  D. Heinegård,et al.  Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. , 1988, Arthritis and rheumatism.

[66]  B Henderson,et al.  Interleukin 1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Saklatvala.  Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage , 1986, Nature.

[68]  T. Bringman,et al.  Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors , 1986, Nature.

[69]  C. Dinarello,et al.  Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. , 1986, The Journal of clinical investigation.

[70]  B. Beutler,et al.  Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts , 1985, The Journal of experimental medicine.

[71]  J. Saklatvala,et al.  Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever , 1985, The Journal of experimental medicine.

[72]  D. Woolley,et al.  Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. , 1984, Arthritis and rheumatism.

[73]  D. Woolley,et al.  Histopathology of the rheumatoid lesion , 1984 .

[74]  T. Martin,et al.  Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. , 2002, Bone.

[75]  S. Mita,et al.  Differential effects between marimastat, a TNF-alpha converting enzyme inhibitor, and anti-TNF-alpha antibody on murine models for sepsis and arthritis. , 2002, Cytokine.

[76]  M. Feldmann,et al.  The role of TNF alpha and IL-1 in rheumatoid arthritis. , 2001, Current directions in autoimmunity.

[77]  M. Feldmann,et al.  Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.

[78]  D. Lacey,et al.  Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. , 1999, Bone.

[79]  S. Goodman,et al.  Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. , 1999, The Journal of clinical investigation.

[80]  G. Firestein,et al.  Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. , 1999, The Journal of clinical investigation.

[81]  S. Goodman,et al.  Decreased angiogenesis and arthritic disease in rabbits treated with an αvβ3 antagonist , 1999 .

[82]  A. Koch.  Review: angiogenesis: implications for rheumatoid arthritis. , 1998, Arthritis and rheumatism.

[83]  B. Hambly,et al.  Separation of tumor necrosis factor α isoforms by two‐dimensional polyacrylamide gel electrophoresis , 1997, Electrophoresis.

[84]  B. Castner,et al.  A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. , 1997, Nature.

[85]  M. Lambert,et al.  Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α , 1997, Nature.

[86]  M. Feldmann,et al.  Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.

[87]  M. Feldmann,et al.  Rheumatoid Arthritis , 1996, Cell.

[88]  G. Kollias,et al.  Transmembrane TNF is sufficient to induce localized tissue toxicity and chronic inflammatory arthritis in transgenic mice. , 1996, Journal of inflammation.

[89]  G. Kollias,et al.  Transgenic and knockout analyses of the role of TNF in immune regulation and disease pathogenesis. , 1995, Journal of inflammation.

[90]  A. Cope,et al.  Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis. , 1992, Progress in growth factor research.

[91]  J. Riddle,et al.  The erosive front: a topographic study of the junction between the pannus and the subchondral plate in the macerated rheumatoid metacarpal head. , 1988, The Journal of rheumatology.

[92]  G. Nuki,et al.  Tumournecrosis factor insynovial exudates , 1988 .

[93]  D. Woolley,et al.  Histopathology of the rheumatoid lesion. Identification of cell types at sites of cartilage erosion. , 1984, Arthritis and rheumatism.